T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo
T cells modified with chimeric antigen receptor are an attractive strategy to treat Epstein-Barr virus (EBV) associated malignancies. The EBV latent membrane protein 1 (LMP1) is a 66-KD integral membrane protein encoded by EBV that consists of transmembrane-spanning loops. Previously, we have identi...
Main Authors: | , , , , , , |
---|---|
Format: | Online |
Language: | English |
Published: |
Editorial Department of Journal of Biomedical Research
2014
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4250525/ |